Cairo Consensus Statement on Research Integrity of Randomised Clinical Trials

DOI: https://doi.org/10.12669/pjms.40.8.9779
Keywords: consensus, statements, research, integrity

Abstract

doi: https://doi.org/10.12669/pjms.40.8.9779

How to cite this: Chien PFW, Khan KS, Fawzy M, Khalaf Y. Cairo Consensus Statement on Research Integrity of Randomised Clinical Trials. Pak J Med Sci. 2024;40(8):---------. doi: https://doi.org/10.12669/pjms.40.8.9779

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Biography

Patrick Chien, RCSI & UCD Malaysian Campus

Recently retired from working as a Consultant in Obstetrics & Gynaecology at NHS Tayside, Scotland. At that time, my main clinical interest was in minimally access surgery in benign gynaecology, in particular the management of heavy menstrual bleeding and chronic pelvic pain. I was also the Clinical Director for the Scottish Hydatidiform Mole Follow up Service and Director of postgraduate gynaecological surgical courses at the Dundee Institute of Healthcare Simulation, University of Dundee.

 

Currently, appointed as Professor and Head of Department of Obstetrics & Gynaecology at the Royal College of Surgeons of Ireland and University College Dublin Malaysian Campus in Penang, Malaysia. Also serving as Deputy Editor-in-Chief for British Journal of Obstetrics & Gynaecology (BJOG).

 

Has a research interest in integrity of randomised controlled trials and currently still sit on several research governance committees for clinical trials funded by NIHR HTA in the UK.

Published
2024-07-29
How to Cite
Chien, P., Khan, K. S., Fawzy, M., & Khalaf, Y. (2024). Cairo Consensus Statement on Research Integrity of Randomised Clinical Trials. Pakistan Journal of Medical Sciences, 40(8). https://doi.org/10.12669/pjms.40.8.9779
Issue
Vol. 40 No. 8 (2024): September 2024
Section
Commentary